Home | About Jay Hochman -Pediatric Gastroenterology Blog | Archives
October 12, 2013 7:00 am
As noted in previous blogs (see below), there is not a consensus with regard to screening for NAFLD in overweight and obese patients. While some have argued for aggressive screening leading to an expensive tiered evaluation, other experts have been reluctant to endorse this approach, in part due to the magnitude of the problem and due to the perceived lack of therapeutic options. Weighing in on this controversy is a new study (Aliment Pharm Ther 2013; DOI: 10.1111/apt.12518, link -from Jeff Schwimmer’s twitter feed: http://t.co/q1CUKBJtVo).
In the study’s introduction, the prevalence of NAFLD, estimated to be 9.6% of all children aged 2-19 years, along with society guidelines are reviewed.
The authors examined information from the clinical evaluation of 347 children (>10 years) [overweight (7%)/obese (93%)] who were referred by their primary care physician due to either an elevated ALT or suspected NAFLD. Referral was at the discretion of the primary care attending and not based on a specific ALT value. Median age was 13.5 years and 64% were boys.
1st tier: Subsequently, all patients underwent hepatic panel, GGT, CBC/diff, and coagulation studies. 2nd tier: If abnormal, the next set of labs may have included any or all of the following: studies for hepatitis infection (HAV, HBV, HCV), HIV, alpha-1-antitrypsin, ANA, anti-smooth muscle antibody, anti-liver kidney microsomal antibody, quantitative IgG, ceruloplasmin, 24-h urinary copper, tissue transglutaminase antibody, serum IgA, serum amino acids, urine organic acids, serum acylcarnitine, creatine kinase, ESR, CRP, and thyroid studies. (The authors did not evaluate iron status.) 3rd tier: Then, if evidence of chronic liver disease, patients were offered a liver biopsy under general anesthesia.
Results:
Take-home message: while this article does not resolve the issue of whether screening overweight/obese children is the best strategy, it does provide useful information in those with elevated liver tests. Careful investigation for treatable causes (and possibly nontreatable) of liver disease is worthwhile in those with sustained abnormalities in transaminases. At a minimum, tests for autoimmune hepatitis, celiac disease, viral hepatitis, and Wilson’s disease should be at the top of the list.
Related blog entries:
Posted by gutsandgrowth
Categories: Pediatric Gastroenterology Liver Disease
Tags: elevated LFTs, NAFLD, nonalcoholic fatty liver disease
Mobile Site | Full Site
Get a free blog at WordPress.com Theme: WordPress Mobile Edition by Alex King.
[…] Screening for NAFLD | gutsandgrowth […]
By Fatty Liver at Birth | gutsandgrowth on March 26, 2015 at 7:02 am
[…] Screening for NAFLD | gutsandgrowth […]
By When Will MRI Obviate the Need for a Liver Biopsy in Pediatric NAFLD? | gutsandgrowth on July 14, 2015 at 7:00 am
[…] Screening for NAFLD | gutsandgrowth […]
By Interesting Fatty Liver Articles -Spring 2016 | gutsandgrowth on May 23, 2016 at 7:07 am
[…] study of 347 overweight or obese children with suspected NAFLD (blog review of this study: Screening for NAFLD). He notes that 24% (n=61) of those who underwent liver biopsy ultimately had other diagnoses, […]
By Concise Review: Fatty Liver in Pediatrics | gutsandgrowth on June 24, 2016 at 7:02 am
[…] diagnosis (24%) in children undergoing a liver biopsy for suspected NAFLD (see related blogs: Screening for NAFLD and Concise Review: Fatty Liver in […]
By What is the likelihood of an alternative liver etiology in children with obesity/overweight? | gutsandgrowth on June 9, 2021 at 7:00 am